INS and Hypoglycemia: In particular, the very long half‐life of weekly analogues may hinder effective down‐titration when insulin requirements decrease, while the relatively aggressive titration algorithms adopted in clinical trials (designed to achieve strict fasting glucose targets) may have amplified hypoglycaemia risk during the early treatment intensification phase.